CD markers

CD markers製品

  • All (31)
  • CD markers阻害剤 (24)
  • CD markers拮抗剤(2)
  • CD markers作動薬(1)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S2632 BMS-378806 BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.
Commun Biol, 2023, 6(1):535
J Virol, 2021, 95(24):e0052921
J Virol, 2020, 10.1128/JVI.00148-20
S8960 CD38 inhibitor 1 (compound 78c) CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.
Cell Rep Med, 2024, 5(2):101400
Cell Rep Med, 2023, S2666-3791(23)00310-5
Cell Rep Med, 2023, 4(9):101157
S5525 SodiuM Metatungstate Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively.
Immunology, 2022, 10.1111/imm.13493
Cancer Cell, 2021, 39(7):973-988.e9
S6239 PMX-53 PMX-53 is a potent CD88 (C5aR) antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).
Thromb J, 2022, 20(1):24
S0141 NQ301 NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. NQ301 inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets.
J Extracell Vesicles, 2021, 10(5):e12078
S9867 LY-3475070 LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).
Theranostics, 2024, 14(3):1224-1240
Immunology, 2022, 10.1111/imm.13493
S0474 Avacopan Avacopan is an orally administered and selective C5a receptor (C5aR) antagonist.
Cell Death Dis, 2022, 13(5):500
S3301 Cynarin Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. Cynarin blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization.
S0525 ADH-503 (GB1275) ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.
A2127New Anti-human CD28-InVivo Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro.
S8908New AB680 AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73
A2039 Isatuximab (anti-CD38)

Isatuximab (anti-CD38) (SAR650984, hu38SB19) is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38 receptor with a kd of 0.12 nM.

E1276New MK-0159 MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
S7487 YYA-021 YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4.
E1305New RBN013209 RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer.
A2125New Anti-mouse OX40 (CD134)-InVivo Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo.
A2034 Elotuzumab (anti-SLAMF7) Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.
Nat Commun, 2024, 15(1):1367
D4005New Vorsetuzumab mafodotin Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma.
S6347 5'-N-Ethylcarboxamidoadenosine (NECA) 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
D4012New Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
D4016New Iladatuzumab vedotin Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.
D4017New Pinatuzumab vedotin Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.
S6727 AX-024 HCl AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
D4030New Vadastuximab talirine Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients.
D4034New Lorvotuzumab mertansine Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab).
D4039New Praluzatamab ravtansine Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.
D4045New Brentuximab vedotin Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.
A3175New Blinatumomab (Anti-CD3 & CD19) Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts.
D4051New Tisotumab vedotin Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.
D4055New Loncastuximab tesirine Loncastuximab tesirine (ADCT-402, RB4v1.2-SG-3249) is an antibody-drug conjugate (ADC) composed of an anti-CD19 (B lymphocyte surface antigen B4, Leu-12) chimeric monoclonal antibody , conjugated to Pyrrolobenzodiazepine (PDB) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG.
S0525 ADH-503 (GB1275) ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.
A2127New Anti-human CD28-InVivo Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro.
A2039 Isatuximab (anti-CD38)

Isatuximab (anti-CD38) (SAR650984, hu38SB19) is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38 receptor with a kd of 0.12 nM.

A2125New Anti-mouse OX40 (CD134)-InVivo Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo.
A2034 Elotuzumab (anti-SLAMF7) Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity.
Nat Commun, 2024, 15(1):1367
A3175New Blinatumomab (Anti-CD3 & CD19) Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts.
S2632 BMS-378806 BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.
Commun Biol, 2023, 6(1):535
J Virol, 2021, 95(24):e0052921
J Virol, 2020, 10.1128/JVI.00148-20
S8960 CD38 inhibitor 1 (compound 78c) CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.
Cell Rep Med, 2024, 5(2):101400
Cell Rep Med, 2023, S2666-3791(23)00310-5
Cell Rep Med, 2023, 4(9):101157
S5525 SodiuM Metatungstate Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively.
Immunology, 2022, 10.1111/imm.13493
Cancer Cell, 2021, 39(7):973-988.e9
S0141 NQ301 NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. NQ301 inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets.
J Extracell Vesicles, 2021, 10(5):e12078
S9867 LY-3475070 LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).
Theranostics, 2024, 14(3):1224-1240
Immunology, 2022, 10.1111/imm.13493
S3301 Cynarin Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. Cynarin blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization.
S8908New AB680 AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73
E1276New MK-0159 MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
S7487 YYA-021 YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4.
E1305New RBN013209 RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer.
D4005New Vorsetuzumab mafodotin Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma.
S6347 5'-N-Ethylcarboxamidoadenosine (NECA) 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
D4012New Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
D4016New Iladatuzumab vedotin Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.
D4017New Pinatuzumab vedotin Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.
S6727 AX-024 HCl AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
D4030New Vadastuximab talirine Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients.
D4034New Lorvotuzumab mertansine Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab).
D4039New Praluzatamab ravtansine Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.
S6239 PMX-53 PMX-53 is a potent CD88 (C5aR) antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).
Thromb J, 2022, 20(1):24
S0474 Avacopan Avacopan is an orally administered and selective C5a receptor (C5aR) antagonist.
Cell Death Dis, 2022, 13(5):500
S0525 ADH-503 (GB1275) ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b.
A2127New Anti-human CD28-InVivo Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro.
S8908New AB680 AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73
E1276New MK-0159 MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
E1305New RBN013209 RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer.
A2125New Anti-mouse OX40 (CD134)-InVivo Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo.
D4005New Vorsetuzumab mafodotin Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma.
D4012New Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
D4016New Iladatuzumab vedotin Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research.
D4017New Pinatuzumab vedotin Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.
D4030New Vadastuximab talirine Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients.
D4034New Lorvotuzumab mertansine Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab).
D4039New Praluzatamab ravtansine Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation.
D4045New Brentuximab vedotin Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.
A3175New Blinatumomab (Anti-CD3 & CD19) Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts.
D4051New Tisotumab vedotin Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.
D4055New Loncastuximab tesirine Loncastuximab tesirine (ADCT-402, RB4v1.2-SG-3249) is an antibody-drug conjugate (ADC) composed of an anti-CD19 (B lymphocyte surface antigen B4, Leu-12) chimeric monoclonal antibody , conjugated to Pyrrolobenzodiazepine (PDB) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG.

CD markers阻害剤の選択性比較

Tags: CD markers inhibitor|CD markers agonist|CD markers activator|CD markers inducer|CD markers antagonist|CD markers signaling pathway|CD markers assay kit